{"id":"warfarin-duration","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Bleeding (major)"},{"rate":"10-20","effect":"Bleeding (minor)"},{"rate":"<1","effect":"Warfarin-induced skin necrosis"},{"rate":"<1","effect":"Alopecia"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Warfarin is a vitamin K antagonist that blocks the synthesis of vitamin K-dependent coagulation factors (II, VII, IX, and X) in the liver. By depleting these essential clotting factors, warfarin decreases the ability of blood to form clots, thereby preventing thromboembolism. The duration of warfarin therapy varies by indication and is typically managed through INR (International Normalized Ratio) monitoring.","oneSentence":"Warfarin inhibits vitamin K-dependent clotting factors to reduce blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:04.604Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Venous thromboembolism (DVT/PE) treatment and prevention"},{"name":"Mechanical heart valve thromboprophylaxis"},{"name":"Acute myocardial infarction with high thromboembolic risk"}]},"trialDetails":[{"nctId":"NCT07246005","phase":"PHASE2","title":"LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus","status":"NOT_YET_RECRUITING","sponsor":"Queen Mary University of London","startDate":"2026-12-01","conditions":"Left Ventricular Thrombus","enrollment":120},{"nctId":"NCT06429332","phase":"PHASE4","title":"International Care Bundle Evaluation in Cerebral Hemorrhage Research","status":"RECRUITING","sponsor":"Region Skane","startDate":"2025-01-07","conditions":"Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage","enrollment":3500},{"nctId":"NCT01391962","phase":"PHASE2","title":"Sunitinib or Cediranib for Alveolar Soft Part Sarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-07-18","conditions":"Sarcoma, Alveolar Soft Part","enrollment":34},{"nctId":"NCT06783868","phase":"","title":"Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control","status":"NOT_YET_RECRUITING","sponsor":"Kansas City Heart Rhythm Research Foundation","startDate":"2025-10","conditions":"Atrial Fibrillation, Stroke","enrollment":100},{"nctId":"NCT06884384","phase":"","title":"DOAC Versus VKA in Patients With Non-high-risk APS : Prospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2025-09-15","conditions":"Antiphospholipid Syndrome (APS), Cohort Study, Thrombotic and Bleeding Events","enrollment":310},{"nctId":"NCT06101667","phase":"NA","title":"Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-10-15","conditions":"Acute Ischemic Stroke, Basilar Artery Occlusion","enrollment":224},{"nctId":"NCT05794399","phase":"PHASE4","title":"Anticoagulation in Post MI LV Thrombus Trial in Nepal","status":"RECRUITING","sponsor":"Shahid Gangalal National Heart Centre","startDate":"2023-06-19","conditions":"Left Ventricular Thrombus, Myocardial Infarction","enrollment":196},{"nctId":"NCT06449469","phase":"NA","title":"The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2021-05-01","conditions":"Aortic Valve Stenosis, Cardiovascular Diseases, Heart Diseases","enrollment":352},{"nctId":"NCT04250116","phase":"PHASE4","title":"Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yonsei University","startDate":"2020-04-28","conditions":"Atrial Fibrillation","enrollment":960},{"nctId":"NCT05995600","phase":"PHASE4","title":"Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin As Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2024-02-20","conditions":"Antiphospholipid Syndrome, Ischemic Stroke, Transient Ischemic Attack","enrollment":200},{"nctId":"NCT06615596","phase":"EARLY_PHASE1","title":"Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2025-01","conditions":"Atrial Fibrillation (AF)","enrollment":3160},{"nctId":"NCT05824923","phase":"PHASE3","title":"A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure","status":"RECRUITING","sponsor":"Pulnovo Medical (Wuxi) Co., Ltd.","startDate":"2023-08-14","conditions":"Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension","enrollment":264},{"nctId":"NCT06187155","phase":"NA","title":"Impact of Education Level on Clinical Outcomes in Self-INR Managed Patients","status":"RECRUITING","sponsor":"Cairo University","startDate":"2023-12-01","conditions":"Atrial Fibrillation and Flutter, Mechanical Mitral Valve Prosthesis","enrollment":586},{"nctId":"NCT05122780","phase":"PHASE4","title":"Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-07-01","conditions":"Myocardial Infarction With Non-Obstructive Coronary Arteries","enrollment":120},{"nctId":"NCT02972385","phase":"","title":"Pharmacogenomics of Warfarin in Hispanics and Latinos","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2016-09","conditions":"Thrombosis, Hemorrhage","enrollment":400},{"nctId":"NCT04164693","phase":"NA","title":"Efficacy and Safety of Short-term Postoperative Anticoagulant Therapy to Prevente Thrombosis in Arterovenous Fistula","status":"COMPLETED","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2019-01-01","conditions":"Thrombosis","enrollment":287},{"nctId":"NCT04847752","phase":"","title":"Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2021-03-01","conditions":"Ischemic Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis)","enrollment":1000},{"nctId":"NCT06401616","phase":"PHASE4","title":"Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2024-05-21","conditions":"Atrial Fibrillation, Left Atrial Appendage Absent, Anticoagulant Adverse Reaction","enrollment":1220},{"nctId":"NCT05204212","phase":"NA","title":"Left Atrial Appendage Closure in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic KIDNEY Disease","status":"RECRUITING","sponsor":"Prof. Dr. med. Ingo Eitel","startDate":"2022-03-28","conditions":"Non-valvular Atrial Fibrillation (NVAF): Paroxysmal, Persistent, Permanent","enrollment":430},{"nctId":"NCT04066764","phase":"PHASE3","title":"Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-08","conditions":"Venous Thromboembolism","enrollment":200},{"nctId":"NCT04067505","phase":"PHASE3","title":"Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-18","conditions":"May-Thurner Syndrome","enrollment":224},{"nctId":"NCT03702582","phase":"PHASE3","title":"Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2019-04-30","conditions":"Atrial Fibrillation, Stroke, Bleeding","enrollment":100},{"nctId":"NCT02744092","phase":"NA","title":"Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2016-12-13","conditions":"Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT)","enrollment":811},{"nctId":"NCT02295475","phase":"PHASE4","title":"Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome","status":"COMPLETED","sponsor":"Scott C. Woller, MD","startDate":"2014-12-10","conditions":"Antiphospholipid Syndrome, Thrombosis","enrollment":48},{"nctId":"NCT03064035","phase":"PHASE4","title":"Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2017-04-05","conditions":"Acute Bleeding on Long-Term Anticoagulation Therapy, Hemorrhage, Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time)","enrollment":79},{"nctId":"NCT01607359","phase":"","title":"Dabigatran Versus Warfarin Anticoagulation Before and After Catheter Ablation for the Treatment of Atrial Fibrillation","status":"WITHDRAWN","sponsor":"Corewell Health East","startDate":"2012-05","conditions":"Atrial Fibrillation","enrollment":""},{"nctId":"NCT04002011","phase":"PHASE2","title":"DOAC Versus VKA After Cardiac Surgery","status":"WITHDRAWN","sponsor":"Laval University","startDate":"2022-03-09","conditions":"Anticoagulant-induced Bleeding","enrollment":""},{"nctId":"NCT04569279","phase":"PHASE3","title":"Rivaroxaban vs. Warfarin in CVT Treatment","status":"COMPLETED","sponsor":"Damascus University","startDate":"2017-09-01","conditions":"Cerebral Vein Thrombosis","enrollment":71},{"nctId":"NCT03894878","phase":"","title":"Association Between Genetic Variant Scores and Warfarin Effect","status":"COMPLETED","sponsor":"Cipherome, Inc.","startDate":"2019-02-11","conditions":"Atrial Fibrillation, Deep Vein Thrombosis, Intracardiac Thrombus","enrollment":200},{"nctId":"NCT03812848","phase":"NA","title":"Clinical Pharmacist-led Inpatient Anticoagulation Stewardship Program","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2018-01-01","conditions":"Deep Vein Thrombosis, Atrial Fibrillation, Mitral Valve Disease","enrollment":233},{"nctId":"NCT03181386","phase":"PHASE3","title":"Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2017-05-03","conditions":"Atrial Fibrillation, Periodontal Disease, Hemorrhage","enrollment":60},{"nctId":"NCT01947998","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":50299},{"nctId":"NCT04482842","phase":"NA","title":"Gene-guided Warfarin for Anticoagulation Therapy","status":"WITHDRAWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2020-12-10","conditions":"Stroke","enrollment":""},{"nctId":"NCT04409613","phase":"NA","title":"Cost-Effectiveness Study on Establishing a Warfarin Counseling Clinic for Egyptian Patients With Mitral Valve Prostheses","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2020-02-01","conditions":"Cost Effectiveness","enrollment":59},{"nctId":"NCT03473132","phase":"PHASE4","title":"Assessment of Coagulation Factor Levels in Left Ventricular Device (LVAD )Patients Following Temporary Warfarin Reversal With Four Factor Prothrombin Complex Concentrate (4F-PCC)","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2018-03-15","conditions":"Anticoagulation, Anticoagulation Reversal","enrollment":50},{"nctId":"NCT03789695","phase":"PHASE4","title":"RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD","status":"UNKNOWN","sponsor":"Irina Ermolaeva","startDate":"2018-11-14","conditions":"Atrial Fibrillation, T2DM (Type 2 Diabetes Mellitus), Chronic Kidney Diseases","enrollment":200},{"nctId":"NCT02889562","phase":"PHASE2, PHASE3","title":"Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation","status":"COMPLETED","sponsor":"Sanford Health","startDate":"2016-09","conditions":"Coronary Artery Bypass Grafting, Postoperative Atrial Fibrilation, Stroke","enrollment":56},{"nctId":"NCT02297126","phase":"NA","title":"A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-03","conditions":"Adverse Drug Reaction","enrollment":4465},{"nctId":"NCT02331095","phase":"EARLY_PHASE1","title":"Statin Use in Patients With Acute VTE","status":"TERMINATED","sponsor":"Ohio State University","startDate":"2015-01","conditions":"Venous Thromboembolism","enrollment":21},{"nctId":"NCT04121767","phase":"NA","title":"Safety and Efficacy of Edoxaban in Thoracoscopic Ablation","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2017-12-01","conditions":"Atrial Fibrillation, Anticoagulants and Bleeding Disorders","enrollment":60},{"nctId":"NCT02608099","phase":"PHASE4","title":"Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation","status":"COMPLETED","sponsor":"Baim Institute for Clinical Research","startDate":"2015-11","conditions":"Atrial Fibrillation","enrollment":300},{"nctId":"NCT00673439","phase":"PHASE2","title":"Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)","status":"TERMINATED","sponsor":"University of Louisville","startDate":"2007-11","conditions":"Heparin-Induced Thrombocytopenia","enrollment":3},{"nctId":"NCT04051853","phase":"PHASE2","title":"Sorafenib PK in Patients With Advanced HCC and Child-Pugh B","status":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2014-05","conditions":"BCLC Stage C HCC, CP-B Liver Cirrhosis","enrollment":5},{"nctId":"NCT01727427","phase":"","title":"Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients","status":"COMPLETED","sponsor":"G. d'Annunzio University","startDate":"2012-11","conditions":"Unsuspected Pulmonary Embolism","enrollment":695},{"nctId":"NCT02574754","phase":"PHASE1","title":"Assessment of 2012 Bioequivalence Standards for Warfarin","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-05","conditions":"Healthy","enrollment":10},{"nctId":"NCT02592980","phase":"PHASE4","title":"Evaluation of a Pharmacogenetic-based Warfarin Dosing Algorithm in Patients","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2016-01","conditions":"Atrial Fibrillation","enrollment":300},{"nctId":"NCT03885180","phase":"NA","title":"Randomized Evaluation of D-dimer Guiding dUration of Oral antiCoagulation thErapy","status":"UNKNOWN","sponsor":"Wuhan Asia Heart Hospital","startDate":"2019-03-20","conditions":"Valve Heart Disease, Anticoagulants; Increased","enrollment":500},{"nctId":"NCT02072434","phase":"PHASE3","title":"Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2014-03-25","conditions":"Atrial Fibrillation","enrollment":2199},{"nctId":"NCT03747081","phase":"PHASE1, PHASE2","title":"Efficacy Comparison of Warfarin Versus Rivaroxaban CVT","status":"UNKNOWN","sponsor":"Isfahan University of Medical Sciences","startDate":"2018-09-01","conditions":"Cerebral Venous Thrombosis","enrollment":50},{"nctId":"NCT02506985","phase":"PHASE4","title":"XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis","status":"TERMINATED","sponsor":"Susan Smyth","startDate":"2015-07","conditions":"Pulmonary Embolism, Venous Thrombosis","enrollment":10},{"nctId":"NCT03647254","phase":"NA","title":"Efficacy of a Didactic Intervention in Anticoagulated Patients (TAOPE Study)","status":"UNKNOWN","sponsor":"Francisco Javier Navarro Moya","startDate":"2018-09-01","conditions":"Health Education, Patient Education as Topic, Blood Coagulation Tests","enrollment":1},{"nctId":"NCT00356759","phase":"PHASE2","title":"Prolongation of the Interval Between Monitoring of Warfarin in Stable Patients","status":"COMPLETED","sponsor":"Hamilton Health Sciences Corporation","startDate":"2006-12","conditions":"Atrial Fibrillation, Heart Valve Diseases, Venous Thrombosis","enrollment":250},{"nctId":"NCT03147638","phase":"PHASE3","title":"Multi-Center Single Arm Trial to Determine The Effectiveness of Warfarin Therapy Duration For Heparin-Induced Thrombocytopenia (HIT)","status":"UNKNOWN","sponsor":"Marshall University","startDate":"2017-01-11","conditions":"Heparin-induced Thrombocytopenia","enrollment":70},{"nctId":"NCT03573037","phase":"NA","title":"Anticoagulation After RFCA","status":"UNKNOWN","sponsor":"Yong Seog Oh","startDate":"2014-07","conditions":"Atrial Fibrillation","enrollment":246},{"nctId":"NCT03485300","phase":"","title":"The Prevalence of Sub Optimal Anti Coagulation","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-12","conditions":"Poor Drug Response","enrollment":50},{"nctId":"NCT02376803","phase":"PHASE4","title":"The Effect of Medication Timing on Anticoagulation Stability in Users of Warfarin: The \"INRange\" RCT","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2015-02","conditions":"Atrial Fibrillation, Thrombus Due to Heart Valve Prosthesis, Deep Venous Thrombosis","enrollment":217},{"nctId":"NCT02267408","phase":"PHASE1, PHASE2","title":"Randomized Controlled Feasibility Trial of the Fearon Algorithm to Improve Management of Unstable Warfarin","status":"TERMINATED","sponsor":"McMaster University","startDate":"2014-11","conditions":"Hypoprothrombinemia","enrollment":42},{"nctId":"NCT02157272","phase":"PHASE3","title":"Rivaroxaban in Thrombotic Antiphospholipid Syndrome","status":"TERMINATED","sponsor":"University of Padova","startDate":"2014-12","conditions":"Antiphospholipid Syndrome","enrollment":121},{"nctId":"NCT00559988","phase":"PHASE4","title":"Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk","status":"TERMINATED","sponsor":"Biotronik, Inc.","startDate":"2008-02","conditions":"Atrial Fibrillation, Atrial Flutter, Stroke","enrollment":2718},{"nctId":"NCT01124058","phase":"PHASE1","title":"Evaluation of Maintenance Dosing vs Loading Dosing Upon Restarting Warfarin Therapy: A Prospective Randomized Trial","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2010-07","conditions":"Anticoagulation","enrollment":39},{"nctId":"NCT02565836","phase":"","title":"Fixed-dose Activated Versus Variable-dose Inactivated Prothrombin Complex Concentrate for Warfarin-associated Major Bleed","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2015-10","conditions":"Hemorrhage","enrollment":342},{"nctId":"NCT02227550","phase":"PHASE4","title":"Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy","status":"COMPLETED","sponsor":"Atrial Fibrillation Network","startDate":"2014-12","conditions":"Atrial Fibrillation","enrollment":676},{"nctId":"NCT03299296","phase":"PHASE3","title":"Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Comparison Between Rivaroxaban and Enoxaparin","status":"UNKNOWN","sponsor":"Ahmed AbdelMoneim Hassan Ali","startDate":"2017-01-01","conditions":"Thromboses, Deep Vein, Surgery--Complications","enrollment":100},{"nctId":"NCT03088072","phase":"PHASE4","title":"A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure","status":"UNKNOWN","sponsor":"Scripps Health","startDate":"2017-03-23","conditions":"Non-Valvular Atrial Fibrillation, Left Atrial Appendage Closure","enrollment":75},{"nctId":"NCT02511041","phase":"PHASE1","title":"Immunologic Effects of Supplemental Monosaccharide and Nucleoside Derivatives in Patients With Inherited Disorders of Glycosylation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-06-30","conditions":"PGM3","enrollment":2},{"nctId":"NCT03191305","phase":"NA","title":"Comparison of the Efficacy of Rivroxaban to Coumadin( Warfarin ) in Cerebral Venous Thrombosis","status":"UNKNOWN","sponsor":"Foundation University Islamabad","startDate":"2017-08","conditions":"Cerebral Venous Thrombosis","enrollment":50},{"nctId":"NCT03185845","phase":"NA","title":"The Appropriate Anticoagulation Duration for Chronic Obstructive Pulmonary Disease With Pulmonary Thromboembolism","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2017-06-15","conditions":"COPD Exacerbation, PTE - Pulmonary Thromboembolism","enrollment":392},{"nctId":"NCT00634907","phase":"NA","title":"Prospective Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin (Coumadin)","status":"COMPLETED","sponsor":"Gwen McMillin","startDate":"2006-09","conditions":"Venous Thromboembolism, Bleeding","enrollment":263},{"nctId":"NCT02022254","phase":"PHASE1","title":"Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-12-17","conditions":"Diabetes, Diabetes Mellitus, Type 2, Healthy","enrollment":24},{"nctId":"NCT00904982","phase":"NA","title":"Randomized Trial of Interventions to Improve Warfarin Adherence","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2009-10","conditions":"Atrial Fibrillation, Deep Vein Thrombosis, Dilated Cardiomyopathies","enrollment":268},{"nctId":"NCT01474460","phase":"NA","title":"Use of Phytonadione to Reduce International Normalized Ratio (INR) Variability in Patients on Long-term Warfarin Therapy","status":"COMPLETED","sponsor":"James A. Haley Veterans Administration Hospital","startDate":"2011-09","conditions":"Coagulation Delay","enrollment":370},{"nctId":"NCT01516814","phase":"PHASE3","title":"Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-02","conditions":"Pulmonary Embolism","enrollment":40},{"nctId":"NCT01516840","phase":"PHASE3","title":"Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-03","conditions":"Deep Vein Thrombosis","enrollment":60},{"nctId":"NCT00740883","phase":"PHASE3","title":"Extended Duration of Oral Anticoagulant Therapy After a First Episode of Idiopathic Pulmonary Embolism: a Randomized Controlled Trial. \"PADIS-PE\" Study.","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2007-07","conditions":"Pulmonary Embolism","enrollment":374},{"nctId":"NCT00740493","phase":"PHASE3","title":"Prolonged Anticoagulation After a First Episod of Idiopathic Proximal Deep Vein Thrombosis (PADIS TVP)","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2007-07","conditions":"Recurrent Venous Thromboembolism, Idiopathic Deep Vein Thrombosis","enrollment":104},{"nctId":"NCT02979561","phase":"PHASE4","title":"Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy","status":"UNKNOWN","sponsor":"Meshalkin Research Institute of Pathology of Circulation","startDate":"2016-10","conditions":"Angiographically Confirmed Acute Massive Pulmonary Embolism Treated With Endovascular Mechanical Fragmentation and Thrombolytic Therapy","enrollment":200},{"nctId":"NCT02705976","phase":"NA","title":"Prospective Trial of a Validated Algorithm for Warfarin Dosing","status":"COMPLETED","sponsor":"Aalborg University Hospital","startDate":"2014-09","conditions":"Anticoagulation","enrollment":211},{"nctId":"NCT01285661","phase":"PHASE3","title":"Optimal Duration of Anticoagulation in Deep Venous Thrombosis","status":"COMPLETED","sponsor":"University of Padova","startDate":"2010-03","conditions":"Deep Vein Thrombosis of Lower Limb, Lower Extremity Deep Venous Thrombosis Recurrent","enrollment":584},{"nctId":"NCT00700895","phase":"PHASE3","title":"Assessing the Clinical Benefits of a Pharmacogenetics-Guided Dosing Regiment for Calculating Warfarin Maintenance Dose","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2006-08","conditions":"Indications for Warfarin Therapy","enrollment":320},{"nctId":"NCT00580216","phase":"PHASE3","title":"Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation","status":"TERMINATED","sponsor":"Sanofi","startDate":"2007-12","conditions":"Atrial Fibrillation","enrollment":3773},{"nctId":"NCT02054936","phase":"PHASE4","title":"Evaluation of Wound Drainage After Knee or Hip Arthroplasty","status":"WITHDRAWN","sponsor":"University of Michigan","startDate":"2014-03","conditions":"Complications; Arthroplasty","enrollment":""},{"nctId":"NCT02238535","phase":"PHASE2","title":"Use of Ventavis in Patients With Postembolic Residual Pulmonary Hypertension","status":"UNKNOWN","sponsor":"Meshalkin Research Institute of Pathology of Circulation","startDate":"2014-09","conditions":"Residual Pulmonary Hypertension","enrollment":60},{"nctId":"NCT01727453","phase":"PHASE4","title":"Compare VKA vs LMWH in Patients With Anticoagulation Criteria and Episode of Gastrointestinal Bleeding.","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2011-12","conditions":"Acute Gastrointestinal Bleeding","enrollment":40},{"nctId":"NCT00524862","phase":"NA","title":"Standard Drug Therapy vs. Implanted Defibrillator for Primary Prevention of Sudden Cardiac Death","status":"TERMINATED","sponsor":"Unity Health Toronto","startDate":"2007-10","conditions":"Coronary Heart Disease, Congestive Heart Failure, Ventricular Dysfunction","enrollment":5000},{"nctId":"NCT01695824","phase":"PHASE2","title":"Left Atrial Appendage (LAA) Occluders After Catheter Ablation of Atrial Fibrillation","status":"COMPLETED","sponsor":"Meshalkin Research Institute of Pathology of Circulation","startDate":"2011-12","conditions":"Atrial Fibrillation","enrollment":96},{"nctId":"NCT00993200","phase":"PHASE4","title":"Personalized Medicine Interface Tool (PerMIT): Warfarin: A Trial Comparing Usual Care Warfarin Initiation to PerMIT Pharmacogenetic Guided Warfarin Therapy","status":"COMPLETED","sponsor":"Robert Pendleton","startDate":"2009-08","conditions":"Blood Clotting","enrollment":26},{"nctId":"NCT00990158","phase":"PHASE3","title":"Does Low Dose Oral Vitamin K Improve International Normalized Ratio (INR) Stability?","status":"COMPLETED","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2010-07","conditions":"Coagulation, Bleeding, Thrombosis","enrollment":235},{"nctId":"NCT02355730","phase":"NA","title":"Blood Donation From Warfarin Users for the Development of POC INR Monitor","status":"UNKNOWN","sponsor":"Microvisk Technologies Ltd","startDate":"2014-05","conditions":"Atrial Fibrillation, Pulmonary Embolism, Deep Vein Thrombosis","enrollment":1560},{"nctId":"NCT01597310","phase":"PHASE1","title":"Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study","status":"COMPLETED","sponsor":"Knopp Biosciences","startDate":"2012-05","conditions":"Healthy Volunteers","enrollment":15},{"nctId":"NCT01565239","phase":"PHASE2","title":"Fiix-prothrombin Time for Monitoring Warfarin","status":"COMPLETED","sponsor":"Landspitali University Hospital","startDate":"2012-03","conditions":"Thromboembolism, Arterial, Venous","enrollment":1156},{"nctId":"NCT01195324","phase":"PHASE1","title":"A Drug Interaction Study of Warfarin and Canagliflozin in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-09","conditions":"Healthy","enrollment":14},{"nctId":"NCT00403767","phase":"PHASE3","title":"An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-12","conditions":"Atrial Fibrillation, Stroke, Embolism","enrollment":14269},{"nctId":"NCT01654042","phase":"PHASE3","title":"Prolongation of the Interval Between Prothrombin Time Tests in Stable Patients II","status":"WITHDRAWN","sponsor":"McMaster University","startDate":"2014-04","conditions":"Atrial Fibrillation, Valvular Heart Disease, Deep Vein Thrombosis","enrollment":""},{"nctId":"NCT00401414","phase":"NA","title":"Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2007-01","conditions":"Pulmonary Embolism, Deep Vein Thrombosis, Atrial Fibrillation","enrollment":344},{"nctId":"NCT00927862","phase":"PHASE2, PHASE3","title":"Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin","status":"COMPLETED","sponsor":"Intermountain Health Care, Inc.","startDate":"2008-08","conditions":"Thromboembolism","enrollment":2415},{"nctId":"NCT00814177","phase":"PHASE2","title":"Prothrombin Times Outside the Therapeutic Range in Otherwise Stable Patients","status":"COMPLETED","sponsor":"Hamilton Health Sciences Corporation","startDate":"2006-07","conditions":"Atrial Fibrillation, Venous Thromboembolism, Ischemic Stroke","enrollment":160},{"nctId":"NCT01526083","phase":"PHASE1","title":"Effect of Lacosamide 200 mg Twice a Day (Bid) on Single Dose Warfarin 25 mg in Healthy Males","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2012-01","conditions":"Healthy Volunteers","enrollment":16},{"nctId":"NCT00770718","phase":"PHASE1","title":"Factor VII, Prothrombin Complex Concentrate, and Fresh Frozen Plasma in Warfarin-Related Intracranial Hemorrhage","status":"TERMINATED","sponsor":"University of Utah","startDate":"2008-04","conditions":"Intracranial Hemorrhage","enrollment":2},{"nctId":"NCT01339611","phase":"NA","title":"Education Program for Patients Receiving Oral Anticoagulation","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2011-05","conditions":"Cardiovascular Disease, Venous Thromboses, Atrial Fibrillation","enrollment":160},{"nctId":"NCT01375725","phase":"","title":"Study to Determine the Accuracy of Prothrombin Time of Warfarinised Blood","status":"COMPLETED","sponsor":"Universal Biosensors Pty Ltd","startDate":"2010-09","conditions":"Clotting Disorders","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1381,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Warfarin duration","genericName":"Warfarin duration","companyName":"British Thoracic Society","companyId":"british-thoracic-society","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Warfarin inhibits vitamin K-dependent clotting factors to reduce blood clot formation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (DVT/PE) treatment and prevention, Mechanical heart valve thromboprophylaxis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}